These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8321785)

  • 1. Reversing coronary atherosclerosis. How to put findings of recent trials to practical use.
    Kahn JK
    Postgrad Med; 1993 Jul; 94(1):50-2, 55-7, 60-5. PubMed ID: 8321785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?
    Stegmayr B; Lalau JD; Johnson O
    Transfus Apher Sci; 2004 Jun; 30(3):213-20. PubMed ID: 15172626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.
    O'Keefe JH; Cordain L; Harris WH; Moe RM; Vogel R
    J Am Coll Cardiol; 2004 Jun; 43(11):2142-6. PubMed ID: 15172426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active Lipid Management In Coronary Artery Disease (ALMICAD) study.
    Khanal S; Obeidat O; Hudson MP; Al-Mallah M; Bloome M; Lu M; Greenbaum AB; Kugelmass AD; Weaver WD
    Am J Med; 2007 Aug; 120(8):734.e11-7. PubMed ID: 17679135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM
    Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is regression of coronary sclerosis possible?].
    Krayenbühl HP
    Schweiz Rundsch Med Prax; 1993 Nov; 82(47):1348-53. PubMed ID: 8272700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of lipid lowering measures on coronary perfusion].
    Steinmetz A; Maisch B; Noll B
    Z Kardiol; 1997; 86 Suppl 1():43-55. PubMed ID: 9173721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease.
    Brown BG; Zhao XQ; Sacco DE; Albers JJ
    Annu Rev Med; 1993; 44():365-76. PubMed ID: 8476257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization.
    Bates ER
    Am J Cardiol; 2000 Dec; 86(12A):28L-34L. PubMed ID: 11374853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.